araag2/HINT huggingface dataset:
Clinical trial NCT00192101 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of breast carcinoma with evidence of
             unresectable, locally recurrent, or metastatic disease. Lesions should not be amenable
             to surgery or radiation of curative intent.

          -  Presence of metastatic or local-regional recurrent disease, according to the American
             Joint Committee on Cancer

          -  Uni-dimensionally measurable lesions with clearly defined margin that are clearly
             measurable by following methods according to computerized tomography (CT), Chest x-ray
             or clinical examination, according to RECIST criteria

          -  Patients with unresectable, locally recurrent or metastatic breast cancer who, were
             pre-treated with anthracyclines with/without taxanes (paclitaxel, docetaxel)containing
             chemotherapy either in neoadjuvant/adjuvant or 1st line metastatic setting will be
             enrolled into the study. Prior chemotherapy has to be terminated 4 weeks prior. Study
             randomization and disease progression under this therapy has to be documented, also
             patients must have completely recovered from all acute chemotherapy related toxicities
             (with exception of alopecia).

        Prior radiotherapy must be completed at least 30 days before study entry. Patients must
        have recovered from the acute toxic effects of the treatment prior to study enrollment
        (except for alopecia). Lesions that have been radiated cannot be included as sites of
        measurable disease unless clear tumor progression has been documented in these lesions
        since the end of radiation therapy.

        Exclusion Criteria:

          -  Have received treatment within the last 30 days with an investigational drug for any
             indication before study entry.

          -  Concurrent administration of other tumor therapy, including cytotoxic chemotherapy,
             surgery of cancer, radiotherapy, hormonal therapy and immunotherapy (including
             Herceptin)

          -  Active infection that in the opinion of the investigator would compromise the
             patient's ability to tolerate therapy, unless adequately treated.

          -  Serious concomitant disorders that would compromise the safety of the patient or
             compromise the patient's ability to complete the study, at the discretion of the
             investigator.

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment(except in situ carcinoma of cervix or adequately treated basal
             cell carcinoma of skin)
Clinical trial NCT00734032 (phase 2, status: completed)
Conditions: atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: sb480848 40mg ec tablet, sb480848 80mg ec tablet, sb480848 160mg ec tablet, sb480848 placebo tablet
SMILES: CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        Dyslipidemic subject who is currently undergoing statin therapy and no change in
        lipid-lowering therapy or dose during the 4 week prior to randomization

        Exclusion criteria:

          1. Recent (i.e.,<6 months prior to screening) CV event and/or vascular procedure defined
             as:

             A)ST-elevation MI or non-ST-elevation MI B)Unstable angina C)Coronary
             revascularization [(percutaneous coronary intervention (PCI) or coronary artery bypass
             graft (CABG)] D)Stroke of any etiology E)Peripheral arterial disease with critical
             limb ischemia (resting pain or ischemic skin lesions, either ulcers or gangrene)
             F)Resuscitated cardiac arrest

          2. Planned CABG or planned PCI or planned major non-cardiac surgery within study period

          3. No measurable Lp-PLA2 activity in plasma (<10 nmol/min/mL) at screening

          4. Change in a lipid-lowering medication, regimen or dosage during the 4 week prior to
             randomization

          5. Poorly controlled dyslipidemia (LDL-c >=160 mg/dL) at screening
Clinical trial NCT00159458 (phase 2, status: terminated)
Conditions: recurrent breast cancer, metastastic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine and oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven dx of recurrent or metastatic breast cancer

          -  Must have received at least 1 but not more than 3 prior chemotherapy regimens for
             recurrent or metastatic breast cancer. Patients who relapse within 12 months of
             completing adjuvant chemotherapy can only have had up to 2 prior regimens for
             metastatic disease. Patients who relapse within 12 months of completing adjuvant
             chemotherapy containing an anthracycline and a taxane, do not require prior
             chemotherapy for metastatic disease.

          -  Unidimensionally measurable dz (by RECIST)

          -  At least 18 yrs of age

          -  SWOG PS 0-2

          -  AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb
             greater than or equal to 8.0

          -  Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5
             x uln

          -  Creatinine less than or equal to 2.0

          -  Fully recovered from acute toxicities secondary to prior tx

          -  Signed informed consent (including HIPAA authorization)

          -  Peripheral neuropathy grade 0-1

        Exclusion Criteria

          -  Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin
             allowed if completed >12 mos prior to enrollment.

          -  Underlying medical, psychiatric, or social conditions that would preclude patient from
             receiving tx

          -  Peripheral neuropathy greater than or equal to Gr 2

        Exclusion Criteria:

        -
Clinical trial NCT00003995 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan hydrochloride
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IV colorectal cancer with p185 HER2 overexpression

          -  Bidimensionally measurable disease Indicator lesion must be outside of irradiated
             field No symptomatic CNS brain metastases

        PATIENT CHARACTERISTICS:

          -  Performance status: ECOG 0-2

          -  Absolute granulocyte count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT no greater than 3.0 times ULN

          -  Creatinine no greater than 2.0 mg/dL

          -  LVEF at least 45% by MUGA or ECHO

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

          -  No unstable angina

          -  No clinically significant pericardial effusion or arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study

          -  No other prior malignancy within the past 5 years, except:

               -  Curatively treated basal or squamous cell skin cancer

               -  Curatively treated carcinoma in situ of the cervix

               -  No active serious infection or serious underlying medical condition that would
                  prevent compliance

               -  No dementia or significantly altered mental status

        PRIOR CONCURRENT THERAPY:

          -  Concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa allowed

          -  No prior trastuzumab

          -  No more than 1 prior chemotherapy regimen for advanced disease (if progressed during
             or within 6 months of adjuvant therapy considered to have had 1 regimen for advanced
             disease)

          -  No prior irinotecan

          -  Concurrent contraception, estrogen replacement therapy, or megestrol acetate for
             anorexia allowed

          -  Greater than 3 weeks since prior radiotherapy and recovered

          -  Greater than 3 weeks since major surgery (except simple biopsy or venous access
             placement) and recovered

          -  At least 3 weeks since prior investigational nonneoplastic drugs
Clinical trial NCT00614393 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan hydrochloride, placebo
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant must have confirmed wtKRAS CRC.

          -  Participant must have previously failed both irinotecan and oxaliplatin containing
             regimens, and should have progressed on or within 3 months of completing their last
             line of therapy with objective evidence of progression as verified by previous
             radiologic scans.

        Exclusion Criteria:

          -  Participant has had cancer treatment within 2 weeks before the first dose of study
             drug(s) or if the side effects from the drugs have not gone down to a certain level 2
             weeks before the first dose of study drugs.

          -  Participant has had a bad side effect to irinotecan therapy.

          -  Participant has human immunodeficiency virus (HIV).

          -  Participant has Hepatitis B or C.

          -  Participant is pregnant or breast feeding or planning to have a child while on this
             study.
Clinical trial NCT00592007 (phase 2, status: terminated)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: fulvestrant and erlotinib
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Reason stopped: 
    study was terminated due to slow subject accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer

          -  Eligible patients will have stable disease on erlotinib monotherapy at FDA- approved
             doses after a minimum duration of erlotinib therapy of 2 months

          -  18 years or older

          -  ECOG Performance Status ≤2

          -  Adequate Organ Function Requirements

          -  Adequate coagulation function

          -  Postmenopausal status in female patients is required and is defined as no menstrual
             periods for 12 month or surgical menopause

          -  All patients must sign a written informed consent.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women will not be entered on this study

          -  Patients who are currently receiving another investigational drugs

          -  Patients who are currently receiving other anti-cancer agents.

          -  Hormone replacement therapy will not be allowed and have to be stopped 1 month prior
             to entry into the study

          -  Patients who have an uncontrolled infection.

          -  Patients receiving less than 100mg/day of erlotinib

          -  Patients with evidence of progression after 2 months of erlotinib monotherapy.

          -  Patients with a history of bleeding diathesis (i.e., disseminated intravascular
             coagulation [DIC], clotting factor deficiency) or long-term anticoagulant therapy
             (other than antiplatelet therapy).

          -  Patients with a history of hypersensitivity to active or inactive excipients of
             fulvestrant (i.e. castor oil or Mannitol).

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study.
Clinical trial NCT00595530 (phase 2, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: ketamine
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    lack of enrollment and patient interest in study
  
Eligibility criteria:

        Inclusion Criteria:

          -  CCMC: Children ages 7-22 years (inclusive) with documented sickle cell disease

          -  UCHC: Adults 18 years (inclusive) and above with documented sickle cell disease

          -  Sudden onset of acute pain consistent with a vasoocclusive episode -Pain requiring
             hospitalization, placement on pain protocol, and patient- controlled opiates

          -  Pain score of greater than or equal to 5 out of 10 when ketamine infusion is started

          -  Cognitive ability to report pain on a 0 to 10 Numerical Rating Scale (NRS)

          -  At least one prior hospitalization for vasoocclusive pain at CCMC in the previous 24
             months

          -  Parental consent and child assent

        Exclusion Criteria:

          -  Children hospitalized for a primary diagnosis other than vasoocclusive episode

          -  Concurrent Acute Chest Syndrome (ACS)

          -  Hemoglobin < 5 mg/dL

          -  Concurrent history of glaucoma or raised intracranial pressure

          -  Signs or symptoms consistent with stroke

          -  History of liver or renal dysfunction

          -  Pregnancy (females age 12 and above must have pregnancy test)

          -  Simultaneous participation in investigational drug study

          -  Primary language spoken other than English

          -  No hospitalizations to CCMC for vasoocclusive pain in the previous 24 months
Clinical trial NCT00707161 (phase 2, status: terminated)
Conditions: cancer, melanoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    discontinued due to low enrollment
  
Eligibility criteria:

        Inclusion criteria:

          -  Signed study-specific consent form prior to registration.

          -  Pathologically confirmed malignant melanoma.

          -  Measurable melanoma lesion deemed to require radiation by treating physicians for
             purposes of local control or palliation. The lesion may be the primary melanoma, a
             nodal metastasis, or a distant metastasis. Recurrent lesions are allowed.

          -  Lesion has to be measurable clinically or radiographically in 2 dimensions.

          -  Karnofsky Performance Scale (KPS) > 70.

          -  Laboratory values

               -  White blood cells (WBC) > 3000/mm3

               -  Absolute granulocyte count > 1,500

               -  Platelets > 100,000/mm3

               -  Total bilirubin < 2.0 x institutional upper limit of normal

               -  AST or ALT (aminotransferase/alanine aminotransferase) < 2.5 x institutional
                  upper limit of normal

               -  Serum calcium < 1.3 x institutional upper limit of normal

               -  Serum creatinine < 1.5 mg/dL or Creatinine clearance > 50 cc/min,calculated as
                  follows: CCr = 0.85 x (140-age) x (weight in kg) 72 x serum creatinine in mg/dL

        Exclusion criteria:

          -  Systemic therapy for malignant melanoma within one month preceding trial enrollment.

          -  Prior irradiation to the planned field.

          -  Concomitant chemotherapy (in addition to cisplatin) or biologic therapy is allowed.

          -  Significant infection or other co-existent medical condition which would prevent the
             use of full dose chemotherapy.

          -  Pre-existing sensory neuropathy (CTC 3.0 ≥ Grade II)

          -  Pregnancy or lactation.
Clinical trial NCT00080509 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: kos-862
SMILES: [H]\C(=C(\C)[C@]1([H])C\C([H])=C(C)/CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Measurable disease

          -  One previous treatment of a platinum based drug such as cisplatin or carboplatin

          -  At least 3 weeks since last surgery/radiation/chemotherapy

        Exclusion Criteria:

          -  Brain metastases

          -  Changes in the rhythm of your heart that are considered significant as determined by
             an ECG tracing
Clinical trial NCT00283803 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: exisulind, luteinizing hormone-releasing hormone (lhrh) agonist, antiandrogen
SMILES: CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  A willingness and ability to sign an informed consent document;

               -  21 years or of legal age;

          -  Histologically or cytologically documented prostate cancer.

          -  ECOG Performance status score of 0 or 1.

          -  Received at least one cycle of IAS with an LHRH agonist and anti-androgen

          -  Willingness to remain off chronic NSAIDs (with the exception of ibuprofen or
             naproxen), including COX 2 inhibitors and salicylates (e.g., aspirin, mesalamine,
             azodisalicylate, salsalate, sulfasalazine) for duration of the study. Patients on low
             dose aspirin for cardiovascular prevention may be included in the study.

          -  Have not taken sulindac (Clinoril™) on regular basis for any indication for one week
             prior to enrollment and willing to remain off of sulindac for the duration of the
             study.

          -  Patients with prior radiation must be 2 weeks from their last radiation-treatment and
             have recovered from all associated toxicity.

        Exclusion Criteria:

          -  Known hypersensitivity to sulindac (Clinoril™)

          -  ECOG Performance status score > 1;

          -  Patients previously on SWOG 9346 or 9921 trials, or any other trials using IAS for
             which adding exisulind may be confounding.

          -  Patients may not have any evidence of hormone-refractory prostate cancer, i.e. 2
             consecutive rises in PSA on LHRH agonist and anti-androgen

          -  Active peptic ulcer disease;

          -  Use of an investigational medication or device within one month of initiating study
             therapy;

          -  Elevations of serum creatinine to above the upper limit of normal;

          -  Platelet count < 100,000/L; hgb < 9.0 g/dL; absolute neutrophil count < 1500/mm3

          -  Known hepatic, biliary tract, renal or hematologic dysfunction which in the opinion of
             the Investigator or Sponsor are clinically significant or would obscure laboratory
             analyses or are associated with lab abnormalities;

          -  Any condition or any medication that may interfere with the conduct of the study.

          -  Bilirubin > ULN. Patients with elevated indirect bilirubin due to Gilbert's Syndrome
             will be eligible.

          -  AST or ALT >2.5 X ULN
Clinical trial NCT00529802 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: rad001
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic renal cancer refractory to sorafenib or sunitinib therapy

          -  At least one measurable site of disease according to RECIST criteria that has not been
             previously irradiated.

          -  18 years of age or older

          -  Minimum of two weeks since any major surgery, completion of radiation, or completion
             of all prior standard systemic anticancer therapy and adequately recovered from the
             acute toxicities of any prior therapy.

          -  World Health Organization (WHO) performance status <= 2

          -  Adequate bone marrow function

          -  Adequate liver function

          -  Adequate creatinine clearance

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior treatment with any investigational drug within the previous 4 weeks

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

          -  Patients who have a history of another primary malignancy ≤ 3 years, with the
             exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          -  A known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)

          -  Patients with an active, bleeding diathesis or on oral anti-vitamin K medication

          -  Women who are pregnant or breast feeding, or women/men able to conceive and unwilling
             to practice an effective method of birth control from enrollment through 6 months
             following the end of treatment

          -  Patients who have received prior treatment with an mTOR inhibitor.

          -  Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins
             (sirolimus, temsirolimus) or to its excipients

          -  History of noncompliance to medical regimens

          -  Patients unwilling to or unable to comply with the protocol